ABSTRAm. It is now widely accepted that tetrahydrobiopterin (BH4), the natural cofactor of aromatic amino acid hydroxylases, in the absence of its regenerating enzyme dihydropteridine reductase (DHPR), will function only stoichiometrically in the phenylalanine (Phe) hydroxylating system. This has limited the use of pterin cofactor in diagnosis and treatment of patients suffering from inherited DHPR deficiency, one of the most common forms of hyperphenylalaninemia caused by BH4 deficiency. This is despite the observation of a dramatic fall in serum Phe concentration after BH4 loading in such patients. In this study, quantitation of this phenomenon was obtained by comparing the kinetics of serum Phe after either a simple Phe or a combined Phe plus BH4 oral loading in patients with Phe hydroxylase or with DHPR deficiency. Only in the latter was the total body clearance of Phe enhanced up to 5 times by the cofactor administration, resulting in the molar equivalent of Phe hydroxylated/mol of BH4 ranging from a t least 6 to 10, against the postulated 1. As a consequence, BH4 administration should be attempted therapeutically in DHPR-deficient patients, thus avoiding a lifelong Phe-restricted diet. Preliminary experience with such treatment is given with two cases. (Pediah Res 33: 125-128, 1993) Abbreviations BH4, tetrahydrobiopterin DHPR, dihydropteridine reductase Phe, pheny lalanine PKU, phenylketonuria qBH2, quinonoid dihydrobiopterin TBC, total body clearance Trp, tryptophan Tyr, tyrosine BH4 is the essential cofactor of Phe, Tyr. and Trp hydroxylases. After a coupled reaction with these enzymes. BH4 is oxidized to qBH2. Regeneration of BH4 from the qBH2 derivative is catalyzed by DHPR (EC 1.66.99.7) ( 1). In humans. DHPR deficiency is one of the causes of hyperphenylalaninemia caused by defects in BH4 metabolism (2) . It has been accepted that the total absence of DHPR activity will restrict BH4 to function only stoichiometrically in the Phe hydroxylating system. thus mini-mizing the potential value of cofactor administration in the treatment of patients (2) (3) (4) (5) . This belief has been held despite the early demonstration of a dramatic lowering of serum Phe by an i.v. dose of 2 mg/kg BH4 in DHPR deficiency (6) and despite more recent observations that such patients show a similar response when given an oral loading test with 5-20 mg/kg BH4 (7-10). Further support for the hypothesis that BH4 is acting catalytically was raised by the effects of BH4 in a DHPR-deficient child ( I I), which were not consistent with a simple stoichiometric conversion of Phe.
We have therefore used simple Phe loading and combined Phe plus BH4 loading to determine the spontaneous and the cofactorinduced Phe hydroxylating activity in PKU and DHPR-deficient patients. As exogenous BH4 increased the hydroxylation rate of Phe only in the latter, it was possible to quantitate the catalytic activity of cofactor in DHPR deficiency by estimating the molar equivalent of Phe hydroxylated/mol of administered BH4. This finding was subsequently confirmed by treating the two DHPRdeficient patients with synthetic cofactor after the Phe-restricted diet had been stopped.
MATERIALS A N D METHODS
Patient .sc~I.ction. The study population consisted of four patients, aged 16 mo to 7 y (three males and one female). Data are shown in Table 1 . Three were identified as hyperphenylalaninemic through the neonatal mass screening for PKU. and the fourth (M.P.). who was previously reported ( 12) . was identified at the age of 10 mo. The diagnosis was subsequently defined through the administration of an oral BH4 loading test (13) coupled with a blood spot test for DHPR activity assay (14) . Two patients (M.P., M.B.) had an ultimate diagnosis of DHPR deficiency "nonresponding" to cofactor administration (1 5); the other two (S.Z., F.M.) were diagnosed as having PKU. with a mild phenotype according to their Phe tolerance (16) . Patients' Phe tolerance was determined just before the study and defined as the maximal amount of dietary Phe they could ingest while keeping serum Phe levels below 480 pmol/L. The two PKU patients were selected for this study because they had a Phe tolerance value close to that of DHPR-deficient patients (Table  1) . The response to BH4 monotherapy was evaluated both clinically. by watching the appearance of symptoms of biogenic amine deficiency. and biochemically, by measuring the serum Phe and the cerebrospinal fluid homovanillic and 5-hydroxyindole acetic acid concentrations.
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RESULTS
The results of the different Phe and BH4 loading tests are shown in Table 2 Thus. the overall Phe serum elimination rate and the BH4-promoted serum Phe hydroxylation rate were evaluated in the 3-to I I-h interval. The administration of BH4 resulted in unchanged serum elimination rate of the Phe load in PKU patients as compared with the simple Phe loading, whereas in DHPR-deficient patients the elimination rate increased in terms of both velocity and percentage of the Phe loading dose, by 2-fold with the dose of 7.5 mg/kg and by 3-fold with the dose of 20 mg/kg BH4. Although BH4 administration did not induce any elimination of the Phe load in PKU patients. in DHPRdeficient patients. the rate of Phe eliminated increased consistently and linearly with the doses of administered cofactor. This elimination could not be by any mechanism other than hydroxylation. The estimated molar ratio of the amount of serum Phe hydroxylated in the 3-to 1 I-h interval to the amount of BH4 administered ranged in DHPR-deficient patients from 5.57 to 8.88. If conversion was stoichiometric. a ratio of I would be expected (Table 2) . Serum Tyr concentrations consistently increased in the DHPR-deficient patients and slightly increased in one PKU patient after the combined Phe plus BH4 loading test (data not shown). However, serum Tyr fluctuations did not appear to be clearly dose-and time-related to BH4 administration.
Preliminary results from the treatment of patients were consistent with these experimental findings. At the time of this writing (February 1992), M.B. had been on BH4 monotherapy for I y. Serum Phe levels were constantly in a harmless range (<240 pmol/L). The concentration of cerebrospinal fluid biogenic amine metabolites decreased with the discontinuation of neurotransmitter therapy. On diet plus neurotransmitter therapy, homovanillic acid and 5-hydroxyindole acetic acid were 168 and 125 nmol/L, respectively. After 12 mo on continuous BH4 therapy (20 mg/kg), the values were 126 and 7 nmol/L. respectively (age-matched controls 300-800 and 100-300 nmol/L. respectively). In the absence of symptoms. it was judged safe to avoid restarting neurotransmitter therapy. as clinical symptoms of biogenic amine deficiency appear within a few hours when the exogenous supply is inadequate or the endogenous production is severely impaired (Ponzone A, unpublished observations). Further. the irreversible brain damage in DHPR deficiency seems due to either hyperphenylalaninemia or folate depletion rather than neurotransmitter deficiency ( 18).
Due to the limited BH4 availability, M.P. has been on BH4 monotherapy only for I mo. Also. in this patient the hyperphenylalaninemia could be fully corrected. but the early fall of the concentrations of homovanillic and 5-hydroxyindole acetic acid in cerebrospinal fluid together with the appearance of neurologic symptoms required resumption of neurotransmitter therapy. * , A11 patients had a simple Phe oral loading and a combined Phe + BH4 oral loading with the higher cofactor dosc (20 mg/kg). The two DHPRpatients also had a combined loading nith a cohctor dose of 7.5 mg/hg. The tests were performed after an overnight fast. and patients were kept on ;I restricted dietar! Phe intake. thus allowing calculation of the TBC of the administered Phe. The elimination rate of serum Phe was determined in the 3-to I I-h interval after Phe loading. The rate of Phe hydroxylation induced hy BH4 administration in the same interval resulted from the dilkrence between the serum elimination rate after the combined and after the simple loading test. The molar equivalent of Phe hydroxylated in the 3-to I I-h interval per mol of administered BH4 was then calculated.
with only Phe and with BH4 in addition to Phe, we demonstrated that six to 10 times more Phe is hydroxylated/mol of administered cofactor in DHPR deficiency than is expected from the equimolar ratio (3-5). BH4 administration to PKU patients served as a control to ensure that the resulting decrease in Phe levels in DHPR deficiency was due solely to hydroxylation and not to incorporation into bound pools. transamination. or decarboxylation. Alternate loading of DHPR-deficient patients with only Phe and with Phe plus BH4 also allowed us to compute the rate of hydroxylation of the Phe load that was only dependent o n exogenous cofactor activity. There are at least two BH4 loading-response classes of DHPR deficiency. In some patients. the hyperphenylalaninemia can be corrected by giving 7.5 mg/kg BH4. whereas other patients fail t o respond to this load but d o respond to 20 mg/kg BH4 (8-10, 15). As DHPR-deficient patients of only the latter type are included in this study. it can be argued that, in patients belonging t o the first class, the molar ratio of Phe hydroxylated to the administered BH4 might be an additional three times higher. Moreover. in this study. calculations were made by assuming the full availability of the administered BH4. though previous studies have shown that the absolute bioavailability of exogenous BH4. mainly because of the limited gut absorption. is as low as 6% ( 19) . This could increase the rate of Phe converted/mol of BH4 administered by an additional 15 times. resulting in an actual molar ratio of Phe to BH4 of at least 90: 1. A possible threshold effect of BH4 within this therapeutic range is excluded. as the increase in the Phe hydroxylation rate was related, on a molar basis, to the administered cofactor dose. This observation also indicates that the dose of 20 mg/kg is not sufficient to saturate the body enzyme system in DHPR-deficient patients.
It is clear that BH4 recycling occurs in DHPR-deficient patients. Our findings, together with previous observations. raise a number of questions that cannot be satisfactorily answered at this time. Despite BH4 being detected in DHPR-deficient patients (20) . it appears not to be used in hydroxylation of Phe. This could be due to the exogenously administered BH4 being somehow different from the endogenous BH4 demonstrated in patients. An NADPH-dependent DHPR has been detected (2 1). and it is not clear why this enzyme cannot take over when the NADH-dependent enzyme is absent. It is completely unclear what enzyme is responsible for recycling qBHz in DHPR-deficient patients. The possibilities for this function include: I ) dihydrofolate reductase with production of BH4 after the rearrangement of qBHz to the 7.8 form. the substrate of this enzyme. which has been identified in DHPR deficiency (20) : -7) 5.10 methylene tetrahydrofolate reductase. known to carry out the DHPR function (22) : or 3) residual DHPR activity of the mutant enzyme.
Assays of DHPR in our patients' red blood cells and fibroblasts indicated "zero" activity. In fact. this means <0.5% of normal activity. Considering that (discounting other routes) if DHPR was really zero the fetus may not be viable in litcro. it is likely that there is some residual activity that cannot be accurately quantitated. Thus, if for example residual activity was 0.1 % of normal. and considering the enzyme is ubiquitous, this may be sufficient for the recycling we observe. Ethical considerations prevent us from measuring liver DHPR to see if it is different from a level of <0.5%.
According to the previous belief that. in DHPR deficiency. BH4 will attain only stoichiometric conversion of Phe to Tyr. Kaufman (3. 4) has estimated that the prohibitively expensive dose of 70-120 mg/kg BH4/d would be needed simply to keep pace with the Phe hydroxylation reaction. According to the present findings, the above figure should be reduced by six to 10 times, corresponding to a daily dosage of 8-20 mg/kg BH4. It should be noted that our patients were given an oral Phe load dose (I00 mg/kg) exceeding the estimated daily Phe requirement in infants and children (22-90 mg/kg) (1) and approaching the mean daily Phe intake of children on a free diet. This figure was confirmed by preliminary patient studies, as continuous BH4 therapy at the dose of 20 mg/kg/d allowed patients to stay on a free diet, with a daily Phe intake ranging between l I0 and 150 mg/kg compared with the basal Phe tolerance of 50-55 mg/kg.
If exogenous BH4 can be used in DHPR deficiency to convert Phe to Tyr. it is likely that it will also be working in the Tyr and 128 PONZONE ET .4L.
Trp hydroxylation reactions. However. due to the poor brain entry ofsynthetic cofactor (23). BH4 therapy might be ineffective in restoring sufficient dopamine and serotonin production at the central level. This is a critical point. because every DHPRdeficient patient should be carefully evaluated when BH4 monotherapy is attempted to determine ifcofactor can be used simply to avoid a low Phe diet or also to help maintain adequate neurotransmitter levels.
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